



Inhibitory kinetic spectrophotometric method for the quantitative estimation of D-penicillamine at micro levels



Abhinav Agarwal^{a,b}, Surendra Prasad^{c,*}, Radhey M. Naik^{b,*}

^a Department of Medicine, University of Louisville, KY 40202, USA

^b Department of Chemistry, University of Lucknow, Lucknow 226007, India

^c School of Biological and Chemical Sciences, Faculty of Science, Technology and Environment, The University of the South Pacific, Suva, Fiji

ARTICLE INFO

Article history:

Received 26 March 2016

Accepted 5 April 2016

Available online 7 April 2016

Keywords:

D-penicillamine

Inhibitory effect

Ligand substitution reaction

Potassium hexacyanoruthenate(II)

Nitroso-R-salt


ABSTRACT

Biologically active thiol, D-penicillamine (D-PA), based on the hard soft acid base (HSAB) principle, binds strongly with Hg(II) ions leading to the inhibition of the rate of Hg(II) catalyzed substitution of cyanide in hexacyanoruthenate(II) i.e. $[\text{Ru}(\text{CN})_6]^{4-}$ by nitroso-R-salt (NRS). This formed the basis for the development of a novel kinetic spectrophotometric method for the quantitative determination of D-PA at micro levels. The reaction was followed spectrophotometrically at 525 nm (λ_{max} of $[\text{Ru}(\text{CN})_5\text{NRS}]^{3-}$ complex) under optimized reaction conditions at 8.75×10^{-5} M $[\text{Ru}(\text{CN})_6]^{4-}$, 3.50×10^{-4} M [NRS], pH 7.00 \pm 0.02, ionic strength (μ) 0.1 M (KCl) and temperature 45.0 ± 0.1 °C. The modified mechanistic scheme is proposed to understand the inhibition caused by D-PA on Hg(II) catalyzed substitution of cyanide by NRS in $[\text{Ru}(\text{CN})_6]^{4-}$. The detection limit of the proposed method was found to be 2.5×10^{-7} M. The method has successfully been applied for the determination of D-PA in real samples with quantitative results.

© 2016 Elsevier B.V. All rights reserved.

1. Introduction

The sulfur-containing compounds are involved in several important biochemical processes, including but not limited to redox regulation and drug conjugation/detoxification [1]. Thus, there has been continuous development of analytical methodology using different techniques for the detection and determination of sulfur-containing compounds in different samples [2–5]. Penicillamine is a medication of the chelator class and sold under the trade names of Cuprimine and Depen [6]. It exists in two enantiomeric forms; D-penicillamine and L-penicillamine. Fundamentally, Cuprimine and Depen is D-penicillamine (D-PA) because L-penicillamine (L-PA) is quite toxic [4,6]. The World Health Organization has listed D-PA as an essential medicine, the most important medication needed in a basic health system [7]. D-PA is a sulfur containing amino acid which belongs to aminothiols family where a hydrogen atom in the β -carbon of cysteine is replaced by the methyl group [4,8] and has found many therapeutic applications [8–10]. Therefore, D-PA, whose structure is shown below, is among the most often used thiols as therapeutic substance [7,11].



Structure of D-Penicillamine

D-PA i.e. 3-mercapto-D-valine is a characteristic acid degradation product of β -lactam antibiotics [12]. It is used for the treatment of rheumatoid arthritis [13], cystinuria and in heavy metal poisoning [6,13,14]. Due to its ability of chelation, it is also used for the elimination of copper in the treatment of hepatolenticular degeneration i.e. Wilson's disease [13,14] and has been investigated as an antiangiogenic agent [14–16]. Based on its wide applications in the treatment of a number of diseases and disorders in the human body, it has been categorized as a biologically active thiol [6,17]. One perceived action of thiols in vivo is that they act as anti-oxidants [18] which protect cells and tissues by actively scavenging oxygen species [19,20]. Thus, the development of an analytical method for the quantitative determination of D-PA is of great importance and may receive the attention of pharmaceutical chemists.

There are a number of methods that have been reported for the determination of D-PA in pharmaceutical preparations, analytical and biological samples. These methods include colorimetry [21–29], fluorimetry [12,30], chromatography [8,17,31–38], flow injection analysis

* Corresponding authors.

E-mail addresses: prasad_su@usp.ac.fj (S. Prasad), naik_rm@rediffmail.com (R.M. Naik).

[39–41], electrophoresis [42–44], potentiometry [11,45,46], voltammetry [10,47–53], NMR-spectrometry [54,55] and spectrophotometry [9, 21,23,24,26,27,56] while very few kinetic methods have been reported using different detection techniques [4,11,57]. The analytical methods developed for the detection and determination of D-PA before 1981 have been reviewed by Chiu and Grady [58] and Kucharczyk and Shariman [59]. Some of the main drawbacks in many of the reported methods are high initial investment, heavy instrumentation, high cost of per sample analysis, etc.

The kinetics and mechanism of Hg(II) catalyzed substitution of cyanide in $[\text{Ru}(\text{CN})_6]^{4-}$ by NRS have been recently reported by us [60]. This reaction has successfully been utilized for the development of a novel method for the determination of Hg(II) based on its catalytic effect [61] and sodium thiosulphate (STH), thioglycolic acid (TGA) based on their inhibitory effect on this indicator reaction system [62]. Hg(II) is a soft acid and has very good affinity towards sulfur containing ligands [62,63]. Based on the hard soft acid base (HSAB) principle, which has widely been used in chemistry for explaining the stability of complexes [64], it has been observed that D-PA strongly inhibits the rate of Hg(II) catalyzed substitution of cyanide in $[\text{Ru}(\text{CN})_6]^{4-}$ by nitroso-R-salt (NRS) [60]. To the best of our knowledge, no analytical method has been reported for the determination of D-PA, in pure or pharmaceutical preparations, based on ligand substitution reaction involving substitution of cyanide in $[\text{Ru}(\text{CN})_6]^{4-}$ by NRS except the one recently reported by us which is based on the slow uncatalyzed ligand substitution reaction between $[\text{Fe}(\text{CN})_5(\text{H}_2\text{O})]^{3-}$ and D-PA [4]. We have been interested in developing methods for various analytes of environmental, biological and medicinal interest [4,5,61–63,65–67]. Keeping the above explained backgrounds in mind, in the present communication, a successful attempt has been made to develop a novel, simple and precise kinetic method for the trace level determination of D-PA in various samples. It is based on the inhibitory effect of D-PA on the rate of Hg(II) catalyzed substitution of CN^- in $[\text{Ru}(\text{CN})_6]^{4-}$ by NRS. This method may be helpful for the routine quality control analysis of pharmaceutical products and for the analysis of biological samples containing D-PA.

2. Experimental

2.1. Reagents

All the reagents used were of analytical grade and double distilled water was used throughout the study. 1.0×10^{-2} M stock solutions of $\text{K}_4[\text{Ru}(\text{CN})_6] \cdot 3\text{H}_2\text{O}$, nitroso-R-salt, HgCl_2 and D-PA were prepared by dissolving their appropriate amounts in water. To prevent photodecomposition, $\text{K}_4[\text{Ru}(\text{CN})_6] \cdot 3\text{H}_2\text{O}$ solution was kept in dark amber color volumetric flask. The working solutions of each reagent, as required, were prepared by appropriate dilution from the stock solutions. Potassium dihydrogen phosphate–NaOH buffer of pH 7.00 ± 0.02 was prepared according to the literature method [68].

2.2. Instrumentation

A UV–visible spectrophotometer, model DIG SPEC-110D (Sisco Server Science Ltd., India), fitted with a self designed double walled water circulating thermostated cell compartment, was used for the spectral and absorbance measurements. For pH measurements, a Toshniwal digital pH meter model CL46 was used. The standard BDH buffers of pH 4, 7 and 10 were used to standardize the pH meter at regular intervals. The quartz cuvettes were cleaned by immersing them in 10% HNO_3 and finally with distilled water. They were also cleaned with acetone after a few kinetic runs for removing the deposited purple red colored $[\text{Ru}(\text{CN})_5\text{NRS}]^{3-}$ complex. Remi ultra cryostat was used to maintain the temperature of the reaction system through water circulation.

2.3. General procedure

The concentration of Hg(II) was taken as 3.0×10^{-5} M to get significant change in the absorbance values. All the working solutions of the reactants and buffer were first placed in the thermostat maintained at 45.0 ± 0.1 °C, for 30 min prior to their use, to attain thermal equilibrium. Each of the solutions i.e. 2.0 mL of each; NRS, buffer, HgCl_2 and D-PA were pipetted out and mixed in a 10 mL volumetric flask which was also placed in the same thermostat at 45.0 ± 0.1 °C. The reaction was initiated by adding 2 mL of $\text{K}_4[\text{Ru}(\text{CN})_6]$ solution to the reaction mixture. Then the reaction mixture was quickly shaken and transferred immediately into a 10 mm spectrophotometric cuvette placed in the thermostated cell compartment of the spectrophotometer at 45.0 ± 0.1 °C. As shown in Fig. 1, there was no interference between the absorbances of the product and the reactants. Hence, the progress of the reaction was followed by measuring the increase in the absorbance due to the formation of the substituted complex $[\text{Ru}(\text{CN})_5\text{NRS}]^{3-}$ at its λ_{max} 525 nm without making any correction for the absorbance of reactants. The fixed time procedure as a measure of initial rate, was used to record the decrease in the absorbance of the product as a function of increased concentration of D-PA.

3. Results and discussion

3.1. The indicator reaction

The detailed kinetics and mechanism of Hg(II) catalyzed substitution of coordinated cyanide in hexacyanoruthenate(II) by NRS has recently been reported by us [61]. Hence, only a brief description is presented here. However, the details related to the inhibitory action of D-PA is presented in the form of expressions to justify the direct relationship between the initial rate of reaction and the [D-PA]. The reaction proceeds at 45 °C leading to the formation of purple–red colored complex, $[\text{Ru}(\text{CN})_5\text{NRS}]^{3-}$, having absorption maximum i.e. λ_{max} at 525 nm corresponding to the metal to ligand charge transfer (MLCT) transition. It has been found that D-PA containing sulfur is a soft base while Hg(II)




Fig. 1. UV–visible absorption spectra of the reactants and the product under the conditions: (A) [nitroso-R-salt] = 1.0×10^{-4} M, (B) $[\text{Ru}(\text{CN})_6]^{4-}$ = 1.25×10^{-5} M, (C) Product $[\text{Ru}(\text{CN})_5\text{nitroso-R-salt}]^{3-}$ formed by mixing $[\text{Ru}(\text{CN})_6]^{4-}$ = 3.3×10^{-3} M, [nitroso-R-salt] = 1.0×10^{-3} M, $[\text{Hg}(\text{II})]$ = 2.0×10^{-4} M, μ = 0.1 M (KCl), pH = 7.00 ± 0.02 and temperature = 45.0 ± 0.1 °C.

is a soft acid. Therefore, D-PA easily complexes with the catalyst Hg(II) and thus inhibits the catalyzed reaction between $[\text{Ru}(\text{CN})_6]^{4-}$ and NRS. The inhibition of the catalyzed reaction rate by sulfur containing drug i.e. D-PA in the present case has been attributed to the formation of stable complex of stoichiometry 1:1 between Hg(II) catalyst and D-PA inhibitor [69]. The catalyst-inhibitor complex resulted in the decrease of free catalyst concentration i.e. $[\text{Hg}(\text{II})]$ which ultimately masks the catalytic activity of Hg(II) catalyst. The inhibitory effect depends upon the $[\text{D-PA}]/[\text{Hg}(\text{II})]$ ratio in the indicator reaction system [62,63]. As the concentration of the inhibitor was increased in the indicator reaction system, the reaction rate started decreasing simultaneously.

The UV-visible spectra of the reactants and the product are shown in Fig. 1. It is clear from Fig. 1 that there is no interference between the absorbances of product and those of reactants. Hence, the progress of reaction was followed by measuring the decrease in absorbance at 525 nm (λ_{max} of the product $[\text{Ru}(\text{CN})_5\text{NRS}]^{3-}$) with the increased concentration of the inhibitor D-PA. The decrease in the rate of indicator reaction is directly proportional to the concentration of the inhibitor i.e. [D-PA] added to the reaction system. This observation formed the basis for the linear relationship between the initial rate of the indicator reaction and the concentration of the inhibitor D-PA and was utilized for D-PA determination in the real samples (tablets).

3.2. Calibration graph for the determination of D-penicillamine

For the determination of D-PA, the fixed time absorbance (A_t) was recorded as a measure of initial rate. The plots of absorbance (A_t) versus [inhibitor] i.e., [D-PA] were found to be linear as shown in Fig. 2 which served as calibration curves. The linear regression equations obtained provided the basis for the determination of D-PA. The expressions relating the initial rate i.e. the absorbance change at a fixed time A_t ($t = 15$ and 20 min) to the concentration of inhibitor, D-PA, in the reaction mixture are shown in Eqs. (1) and (2).

$$A_{15} = 0.119 - 3.95 \times 10^4 [\text{D-PA}] \quad (1)$$

$$A_{20} = 0.149 - 4.84 \times 10^4 [\text{D-PA}] \quad (2)$$

The coefficients of the determination corresponding to the calibration Eqs. (1) and (2) are 0.9996 and 0.9981, respectively,





Fig. 2. Calibration curves for the determination of D-penicillamine at $[\text{Ru}(\text{CN})_6]^{4-} = 8.75 \times 10^{-5}$ M, [nitroso-R-salt] = 3.5×10^{-4} M, $[\text{Hg}(\text{II})] = 3.0 \times 10^{-5}$ M, $\mu = 0.1$ M (KCl), pH = 7.00 ± 0.02 and temperature = 45.0 ± 0.1 °C.

which showed an excellent correlation between the initial rate (fixed time procedure) and [D-PA]. To judge the precision and accuracy of the method, the recovery experiments were performed where D-PA was determined in aqueous solutions in the range $0.294\text{--}2.70 \times 10^{-5}$ M. The determined amounts, along with the corresponding standard deviations and percentage errors are given in Table 1. The detection limit was found to be 2.5×10^{-7} M.

3.3. Mechanism of inhibition

The mechanism of inhibition caused by D-PA i.e. inhibitor (I) to the Hg(II) catalyzed cyanide substitution of $[\text{Ru}(\text{CN})_6]^{4-}$ by NRS with a simple modification (which now involves inhibitor) to our earlier proposed mechanistic scheme for the reaction system without inhibitor [60] is given as follows:



The uncatalyzed substitution reaction of $[\text{Ru}(\text{CN})_6]^{4-}$ is extremely slow and is almost negligible in the present case [60]. Hence, uncatalyzed reaction in the proposed mechanistic scheme involving inhibitor D-PA has not been taken into consideration while deriving the rate equation. The substrate $[\text{Ru}(\text{CN})_6]^{4-}$ present in excess is denoted by 'S' while its initial concentration by $[S_0]$. Considering this indicator reaction as an enzyme catalyzed reaction involving single substrate, the rate of reaction was deduced using Lineweaver-Burk Eq. i.e. double reciprocal [70] where V_0 indicates the initial rate of the catalyzed reaction and V_{max} is the maximum attainable rate at a particular concentration of the catalyst Hg(II) and large excess concentration of the substrate, $[\text{Ru}(\text{CN})_6]^{4-}$. K_m is Michaelis-Menten constant involving a single

Table 1

Quantitative determination of D-PA under the reaction conditions: $[\text{Ru}(\text{CN})_6]^{4-} = 8.75 \times 10^{-5}$ M, [NRS] = 3.50×10^{-4} M, $[\text{Hg}^{2+}] = 3.0 \times 10^{-5}$ M, $\mu = 0.1$ M (KCl), pH = 7.00 ± 0.02 and temperature = 45.0 ± 0.1 °C.

[D-PA] × 10 ⁶ M (taken)	A ₁₅		A ₂₀	
	[D-PA] × 10 ⁵ M (found)	% error	[D-PA] × 10 ⁵ M (found)	% error
0.29	0.29 ± 0.003	0.00	0.31 ± 0.021	+6.90
0.60	0.60 ± 0.015	0.00	0.60 ± 0.010	0.00
1.20	1.25 ± 0.050	+4.2	1.30 ± 0.030	+8.33
1.80	1.80 ± 0.036	0.00	1.86 ± 0.032	-3.33
2.40	2.40 ± 0.029	0.00	2.40 ± 0.041	0.00
2.70	—	—	2.70 ± 0.025	0.00

substrate [70,71]. Thus, the rate equation in the presence of inhibitor is given by Eq. (3).

$$\frac{1}{V_0} = \frac{1}{V_{\max}} + \frac{K_m}{V_{\max} [S_0]} \quad (3)$$

The rate of the indicator reaction in the presence of inhibitor D-PA can be expressed as in Eq. (4) where K'_m is apparent Michaelis–Menten constant [72] as given in Eq. (5).

$$V_i = \frac{V_{\max}}{1 + \frac{K'_m}{[S_0]}} \quad (4)$$

$$K'_m = K_m \left(1 + \frac{[I_0]}{K'_{CI}} \right) \quad (5)$$

After substituting K'_m from Eq. (5) into Eq. (4) results in Eq. (6) where I_0 is the initial concentration of the inhibitor i.e. D-PA, V_i denotes the rate of the indicator reaction in the presence of inhibitor D-PA while the catalyst concentration was kept constant and K'_{CI} is the dissociation constant of catalyst-inhibitor (CI i.e. Hg-(D-PA) complex).

$$V_i = \frac{V_{\max}}{1 + \frac{K_m}{[S_0]} \left(1 + \frac{[I_0]}{K'_{CI}} \right)} \quad (6)$$

The indicator reaction rate Eq. (6), which in presence of the inhibitor, has been transformed to Lineweaver–Burk's form as shown in Eq. (7).

$$\frac{1}{V_i} - \frac{1}{V_{\max}} = \frac{K_m}{V_{\max} [S_0]} + \frac{K_m [I_0]}{V_{\max} [S_0] K'_{CI}} \quad (7)$$

The V_{\max} used in Eq. (7) is not an experimental quantity. However, it is evaluated from the intercept of the plot of $\frac{1}{V_0}$ versus $\frac{1}{[S_0]}$ using Eq. (3) in the absence of the inhibitor as shown in Fig. 3. Then the slope of this plot gave the value of K_m as 0.59 mM. For the validity and good results from Eq. (7), inhibitor 'I' must form a complex of the type (CI) with catalyst 'C'. There should be no substrate inhibition i.e. substrate-inhibitor complex should not be formed.




Fig. 3. The plot of $\frac{1}{V_0}$ versus $\frac{1}{[S_0]}$ for the determination of V_{\max} by variation of substrate concentration in absence of inhibitor at $[Hg(II)] = 3.0 \times 10^{-5}$ M, [nitroso-R-salt] = 3.5×10^{-4} M, pH = 7.00 ± 0.02 , temperature = 45.0 ± 0.1 °C and $\mu = 0.1$ M (KCl).

The plot of $(\frac{1}{V_i} - \frac{1}{V_{\max}})$ versus $[I_0]$ i.e. at different concentration of the inhibitor D-PA was found to be linear as shown in Fig. 4. From the intercepts of this plot, the value of K_m in the presence of inhibitor D-PA was evaluated and was found to be in good agreement with its calculated value using $\frac{1}{V_0}$ versus $\frac{1}{[S_0]}$ plot (Fig. 3). The value of K'_{CI} corresponding to the Hg-(D-PA) complex was calculated from the slope of the plot as 3.46×10^{-6} .

3.4. Interference studies

The interferences caused due to the presence of different cations, anions and organic molecules were tested and found that most of the cations like Sn^{2+} , Pb^{2+} , Sr^{2+} , Cu^{2+} , Zn^{2+} , Mg^{2+} , Fe^{3+} , Cr^{3+} , Al^{3+} and anions like Br^- , I^- , NO_3^- , $C_2O_4^{2-}$ do not interfere in the determination of D-PA in the present indicator reaction system except Co^{2+} , Na^+ , SO_4^{2-} , $S_2O_3^{2-}$ and TGA [61]. The interference caused by Co^{2+} ions may be due to their salt formation with NRS. The interference by TGA may be due to their complex forming tendencies with Hg(II) based the HSAB principle [64] and hence reducing its catalytic activity while interference due to Na^+ ions needs further studies for explanation. Sodium salts of some aminopolycarboxylates like EDTA, IDA, NTA, and HEDTA also interfere to some extent which may also be due to the presence of free Na^+ ions in their solutions.

It is important to mention here that no complexing agent i.e. ligand which forms a complex of high stability with Hg(II) should be present in the indicator reaction system for the accuracy in the determination of D-PA. In addition, the metals that complex with D-PA more stronger than Hg(II) under the present experimental conditions must also be absent in the indicator reaction system.

3.5. Application of the method

In order to evaluate the applicability and validity of the proposed method for the analysis of real samples, the method was applied for the analysis of commercially available pharmaceutical samples of D-PA and the results were compared with United States Pharmacopeia (USP) method [73] which showed good precision (Table 2).




Fig. 4. The plot of $(\frac{1}{V_i} - \frac{1}{V_{\max}})$ versus $[I_0]$ for determination of K'_{CI} and K_m in the presence of inhibitor D-penicillamine at $[Hg(II)] = 3.0 \times 10^{-5}$ M, [nitroso-R-salt] = 3.5×10^{-4} M, pH = 7.00 ± 0.02 , temperature = 45.0 ± 0.1 °C and $\mu = 0.1$ M (KCl).

Table 2

Application of the proposed method for the determination of D-PA in D-PA tablets and the recovery data under optimized reaction conditions: $[\text{Ru}(\text{CN})_6^{4-}] = 8.75 \times 10^{-5} \text{ M}$, $[\text{nitroso-R-salt}] = 3.5 \times 10^{-4} \text{ M}$, $[\text{Hg}(\text{II})] = 3.0 \times 10^{-5} \text{ M}$, $\mu = 0.1 \text{ M}$ (KCl), $\text{pH} = 7.00 \pm 0.02$ and temperature = $45.0 \pm 0.1^\circ \text{C}$.

Sample D-PA tablet	Labeled value (mg/tablet)	Amount found (mg/tablet)	Mean recovery \pm SD (%)	
			Proposed method	USP method [73]
Tablet 1	250	253.50	101.4 \pm 1.4	100.5
Tablet 2	250	249.10	99.6 \pm 1.4	99.4
Tablet 3	250	250.61	100.2 \pm 2.0	100.1
Tablet 4	250	251.17	100.5 \pm 1.1	100.7
Tablet 5	250	249.48	99.8 \pm 1.8	99.6

4. Conclusion

The kinetic method reported here for the determination of D-PA is more accurate and sensitive because the uncatalyzed reaction is insignificant in the present system and the presence of inhibitor directly affects the rate of the catalyzed reaction. The detection limit was found to be $2.5 \times 10^{-7} \text{ M}$ which shows that the proposed analytical method can be successfully adopted for D-PA determination at such a low level. To the best of our knowledge, this is the first kinetic method for the determination of D-PA at such a low level using the indicator reaction between $[\text{Ru}(\text{CN})_6]^{4-}$ and NRS in presence of Hg(II) as a catalyst. This method is simple, easy and inexpensive in comparison to the other sophisticated methods [8,10,11,17,31–38,42–53] available in literature and can be adopted for the routine quality control analysis of pharmaceutical products and for the analysis of biological samples containing D-PA.

Acknowledgements

Authors are thankful to Dr. Sanjay Srivastava, Department of Medicine, Division of Cardiology, University of Louisville, USA for providing potassium hexacyanoruthenate(II) as a gift and for providing instrument facility to perform this work. Dr. Abhinav Agarwal is thankful to the Head, Department of Chemistry, University of Lucknow, Lucknow, India for providing necessary laboratory facilities. Prof. Surendra Prasad is grateful to the University of the South Pacific, Suva, Fiji for the support in various ways.

References

- [1] R. Zabel, G. Weber, Comparative study of the oxidation behavior of sulfur-containing amino acids and glutathione by electrochemistry–mass spectrometry in the presence and absence of cisplatin, *Anal. Bioanal. Chem.* 408 (2016) 1237–1247.
- [2] A.V. Petrova, R. Ishimatsu, K. Nakano, T. Imato, A.B. Vishnikin, L.N. Moskvina, A.V. Bulatov, Flow-injection spectrophotometric determination of cysteine in biologically active dietary supplements, *J. Anal. Chem.* 71 (2016) 172–178.
- [3] M. Sierra-Rodero, J.M. Fernández-Romero, A. Gómez-Hens, Photometric determination of thioglycolic acid in cosmetics by using a stopped-flow reverse flow-injection system and the formation of gold nanoparticles, *Microchem. J.* 97 (2011) 243–248 (and references cited therein).
- [4] R.M. Naik, S. Prasad, B. Kumar, V. Chand, Kinetic assay of D-penicillamine in pure and pharmaceutical formulations based on ligand substitution reaction, *Microchem. J.* 111 (2013) 97–102 (and references cited therein).
- [5] S. Prasad, Kinetic determination of organosulphur ligands by inhibition: trace determination of cysteine and maleonitriledithiolate (MNMT), *Microchem. J.* 85 (2007) 214–221.
- [6] J. Peisach, W.E. Blumberg, A mechanism for the action of penicillamine in the treatment of Wilson's disease, *Mol. Pharmacol.* 5 (1969) 200–209.
- [7] WHO Model List of Essential Medicines, World Health Organization, http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1 October 2013 Retrieved on 22 March 2016.
- [8] K. Kuśmierk, E. Bald, Simultaneous determination of tiopronin and d-penicillamine in human urine by liquid chromatography with ultraviolet detection, *Anal. Chim. Acta* 590 (2007) 132–137.
- [9] A.A. Al-Majed, Spectrophotometric estimation of D-penicillamine in bulk and dosage forms using 2,6-dichloroquinone-4-chlorimide (DCQ), *J. Pharm. Biomed. Anal.* 21 (1999) 827–833 (and references cited therein).
- [10] J.-B. Raouf, R. Ojani, F. Chekin, Voltammetric sensor for D-penicillamine determination based on its electrocatalytic oxidation at the surface of ferrocenes modified carbon paste electrodes, *J. Chem. Sci.* 121 (2009) 1083–1091.
- [11] A. Martinović, N. Radić, Kinetic potentiometric determination of penicillamine and N-acetyl-L-cysteine based on reaction with iodate, *Acta Chim. Slov.* 56 (2009) 503–506.
- [12] A.A. Al-Majed, Specific spectrofluorometric quantification of d-penicillamine in bulk and dosage forms after derivatization with 4-fluoro-7-nitrobenzo-2-oxa-1,3-diazole, *Anal. Chim. Acta* 408 (2000) 169–175 (and references cited therein).
- [13] J. Reglinski, W.E. Smith, M. Brzeski, M. Marabani, R.D. Sturrock, Clinical analysis by ^1H spin-echo NMR. 2. Oxidation of intracellular glutathione as a consequence of penicillamine therapy in rheumatoid arthritis, *J. Med. Chem.* 35 (1992) 2134–2137.
- [14] S.A. Lowndes, A.L. Harris, Copper chelation as an antiangiogenic therapy, *Oncol. Res.* 14 (2004) 529–539.
- [15] R.J.V. Stat, A.O. Muijsers, A.M.A. Henrichs, J.K. VanderKorst, D-penicillamine: biochemical, metabolic and pharmacological aspects, *Scand. J. Rheumatol.* 28 (1979) 13–20.
- [16] G.J. Brewer, Anticopper therapy against cancer and diseases of inflammation and fibrosis, *Drug Discov. Today* 10 (2005) 1103–1107.
- [17] J. Russell, J.A. McKeown, C. Hensman, W.E. Smith, J. Reglinski, HPLC determination of biologically active thiols using pre-column derivatization with 5,5'-dithio-(bis-2-nitrobenzoic acid), *J. Pharm. Biomed. Anal.* 15 (1997) 1757–1763.
- [18] O.I. Aruoma, B. Halliwell, B.M. Hoey, J. Butler, The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid, *Free Radic. Biol. Med.* 6 (1989) 593–597.
- [19] P.A. Southorn, G. Powis, Free radicals in medicine. I. Chemical nature and biologic reactions, *Mayo Clin. Proc.* 63 (1988) 381–389.
- [20] M.J. Ledson, R.C. Bucknall, S.W. Edwards, Inhibition of neutrophil oxidant secretion by D-penicillamine: scavenging of H_2O_2 and HOCl, *Ann. Rheum. Dis.* 51 (1992) 321–325.
- [21] P.B. Issopoulos, S.E. Salta, High-sensitive spectrophotometric determination of micro molar concentrations of D-penicillamine by means of a coupled redox-complexation reaction, *Il Farmaco* 52 (1997) 113–118.
- [22] H.F. Askal, G.A. Saleh, O.H. Abdelmageed, I.H. Rafaat, Colorimetric determination of D-penicillamine in bulk form and in capsules using 4-chloro-7-nitrobenzofurazan, *Saudi Pharm. J.* 2 (1994) 84–89.
- [23] P.B. Issopoulos, P.T. Economou, Sensitive spectrophotometric determination of micro amounts of d-penicillamine using an indirect redox technique, *Anal. Chim. Acta* 257 (1992) 203–207.
- [24] A. Besada, A new simple and sensitive spectrophotometric method for determination of penicillamine by reaction with nitrite and Co(II) ions, *Anal. Lett.* 21 (1988) 435–446.
- [25] A. Besada, N.B. Tadors, A simple colorimetric method for the assay of penicillin G salt and penicillamine by oxidation with iodate, *Mikrochim. Acta* 92 (1987) 225–228.
- [26] A. Besada, N.B. Tadors, Y.A. Gawargious, Spectrophotometric determination of pure and capsule-formulated penicillamine, *Anal. Lett.* 20 (1987) 809–820.
- [27] N. Buyuktimkin, S. Buyuktimkin, Spectrophotometric assay of D-penicillamine and its tablets, *Pharmazie* 40 (1985) 581–582.
- [28] M.A. Raggi, V. Vaccini, A.M. Di-Pietra, Colorimetric determination of acetylcysteine, penicillamine, and mercaptopropionylglycine in pharmaceutical dosage forms, *Pharm. Acta Helv.* 58 (1983) 94–96.
- [29] M.A. Raggi, V. Vaccini, A.M. Di-Pietra, Colorimetric determination of acetylcysteine, penicillamine, and mercaptopropionylglycine in pharmaceutical dosage forms, *J. Pharm. Sci.* 71 (1982) 1384–1386.
- [30] S.Y. Byeon, J.K. Choi, G.S. Yoo, Fluorometric determination of D-penicillamine with 9-fluorenylmethyl pentafluorophenyl carbonateme, *Yakche Hakhoechi* 20 (1990) 73–78.
- [31] Z. Nhang, W.R.G. Baeyens, X. Zhang, Y. Zhao, G. Van-Der-Weken, Chemiluminescence detection coupled to liquid chromatography for the determination of penicillamine in human urine, *Anal. Chim. Acta* 34 (1997) 325–332.
- [32] K. Nakashima, T. Ishimaru, N. Kuroda, S. Akiyama, High-performance liquid chromatographic separation of penicillamine enantiomers labeled with N-[4-(6-dimethylamino-2-benzofuranyl)phenyl]maleimide on a chiral stationary phase, *Biomed. Chromatogr.* 9 (1995) 90–93.
- [33] G. Bringmann, D. Feineis, C. Hesselmann, Determination of 1,3-thiazolidinecarboxylic acids in urine by reversed-phase HPLC after fluorescence labeling with dansyl chloride, *Anal. Lett.* 25 (1992) 497–512.
- [34] K. Nakashima, M. Muraoka, S. Nakatsuji, S. Akiyama, Determination of D-penicillamine in serum by high-performance liquid chromatography using N-[4-(6-dimethylamino-2-benzofuranyl)phenyl]maleimide, *Rinsho Kagaku* 17 (1988) 51–54.
- [35] E. Busker, K. Guenther, J. Martens, Application of chromatographic chiral stationary phases to pharmaceutical analysis: enantiomeric purity of D-penicillamine, *J. Chromatogr.* 350 (1985) 179–185.
- [36] S. Biffar, V. Greely, D. Tibbetts, Determination of penicillamine in encapsulated formulations by high-performance liquid chromatography, *J. Chromatogr.* 318 (1985) 404–407.
- [37] I.C. Shaw, A.E.M. McLean, C.H. Boulton, Analysis of D-penicillamine by high-performance liquid chromatography with glassy carbon electrochemical detection, *J. Chromatogr. Biomed. Appl.* 26 (1983) 206–210.
- [38] J.O. Miners, I. Fearley, K.J. Smith, D.J. Birkett, P.M. Brooks, M.W. Whitehouse, Analysis of D-penicillamine in plasma by fluorescence derivatization with N-[p-(2-benzoxazolyl)-phenyl] maleimide and high-performance liquid chromatography, *J. Chromatogr.* 275 (1983) 89–96.
- [39] T. Perez-Ruiz, C. Martinez-Lozano, V. Tomas, C. Sidrach-de-caradona, Flow-injection fluorimetric determination of penicillamine and tiopronin in pharmaceutical preparations, *J. Pharm. Biomed. Anal.* 15 (1996) 33–38.

- [40] M.S. Garcia, C. Sached-Pedreno, M.I. Albero, V. Rodenas, Determination of penicillamine or tiopronin in pharmaceutical preparations by flow injection analysis, *J. Pharm. Biomed. Anal.* 11 (1993) 633–638.
- [41] P. Vinas, J.A. Sanchez-Prieto, M. Hernandez-Cordoba, Flow injection analysis and batch procedures for the routine determination of *N*-penicillamine, *Microchem. J.* 41 (1990) 2–9.
- [42] B.B. Tewari, Electrophoretic studies on mixed complexes: metal–methionine–penicillamine system, *J. Chromatogr.* 793 (1998) 220–222.
- [43] B.B. Tewari, Paper electrophoresis in the study of mixed ligand complexes in solution. The System Fe(III)- and Cr(III)-methyl cysteine–penicillamine, *Biomed. Chromatogr.* 10 (1996) 221–224.
- [44] C. Chen, G.M. Pollack, Development of a capillary zone electrophoresis assay to examine the disposition of [D–pen2,5]enkephalin in rats, *J. Chromatogr. B Biomed. Appl.* 681 (1996) 363–373.
- [45] T. Jovanovic, Z. Koricanac, B. Stankovic, Determination of D(-)penicillamine by potentiometric titration, *Pharmazie* 46 (1991) 293–294.
- [46] J. Motonaka, S. Ikeda, N. Tanaka, Potentiometric titrations of *N*-acetyl-L-cysteine, glutathione, and D–penicillamine with an iodide-selective electrode, *Bunseki Kagaku* 31 (1982) 669–674.
- [47] A. Ion, F.G. Banciu, A.G. Fogg, H. Kozlowski, Cathodic stripping voltammetry of D–penicillamine and *N*-acetylcysteine in the presence of nickel ion, *Electroanalysis* 8 (1996) 40–43.
- [48] U. Forsman, The stripping voltammetric pattern of cysteine and penicillamine at the mercury electrode in the presence of Cu(II), *J. Electroanal. Chem. Interfacial Electrochem.* 152 (1983) 241–254.
- [49] U. Forsman, A. Karlsson, Direct current and differential pulse polarographic behaviour of benzylpenicilloic acid, *Anal. Chim. Acta* 128 (1981) 135–140.
- [50] A.G. Fogg, N.M. Fayad, Differential pulse polarographic study of the degradation of ampicillin, *Anal. Chim. Acta* 113 (1980) 91–96.
- [51] J.-B. Raoof, R. Ojani, F. Chekin, R. Hossienzadeh, Carbon paste electrode incorporating 1-[4-(ferrocenylethynyl)phenyl]-1-ethanone for voltammetric determination of D–Penicillamine, *Int. J. Electrochem. Sci.* 2 (2007) 848–860.
- [52] J.-B. Raoof, R. Ojani, M. Majidian, F. Chekin, Voltammetric determination of D–penicillamine based on its homogeneous electrocatalytic oxidation with potassium iodide at the surface of glassy carbon electrode, *Russ. J. Electrochem.* 46 (2010) 1395–1401.
- [53] J.-B. Raoof, R. Ojani, M. Amiri-Aref, Catechol as an electrochemical indicator for voltammetric determination of D–penicillamine in aqueous media at the surface of carbon paste electrode, *Russ. J. Electrochem.* 48 (2012) 450–456.
- [54] S.E. Ibrahim, A.A. Al-Badr, Application of PMR spectrometry in quantitative analysis of penicillamine, *Spectrosc. Lett.* 13 (1980) 471–478.
- [55] J. Nelson, Nuclear magnetic resonance spectroscopic method for determination of penicillamine in capsules, *J. Assoc. Off. Anal. Chem.* 64 (1981) 1174–1178.
- [56] M.I. Walash, M.E.–S. Metwally, A.M. El-Brashy, A.A. Abdelal, Kinetic spectrophotometric determination of some sulfur containing compounds in pharmaceutical preparations and human serum, *II Farmaco* 58 (2003) 1325–1332.
- [57] M. Skowron, W. Ciesielski, Spectrophotometric determination of methimazole, D–penicillamine, captopril, and disulfiram in pure form and drug formulations, *J. Anal. Chem.* 66 (2011) 714–719.
- [58] C.C. Chiu, L.T. Grady, Penicillamine, in: K. Florey (Ed.), *Analytical Profiles of Drug Substances*, 10, Academic Press, New York 1981, pp. 601–637.
- [59] N. Kucharczyk, S. Shahinian, An overview of assay method for D–penicillamine, *J. Rheumatol. Suppl.* 7 (1981) 28–34.
- [60] R.M. Naik, A. Agarwal, A.K. Verma, S.B.S. Yadav, B. Kumar, Kinetics of the mercury(II)-catalyzed substitution of coordinated cyanide ion in hexacyanoruthenate(II) by nitroso-R-salt, *In. J. Chem. Kinet.* 41 (2009) 215–226.
- [61] R.M. Naik, A. Agarwal, S. Prasad, Determination of trace amounts of mercury(II) in water samples using a novel kinetic catalytic ligand substitution reaction of hexacyanoruthenate(II), *Spectrochim. Acta A* 74 (2009) 887–891.
- [62] R.M. Naik, A. Agarwal, S. Prasad, A.K. Verma, Trace determination of thiosulphate and thioglycolic acid using novel inhibitory kinetic spectrophotometric method, *Microchem. J.* 93 (2009) 43–48.
- [63] R.M. Naik, J. Sarkar, S. Prasad, Kinetic determination of cysteine and thiosulphate by inhibition of Hg(II) catalysed ligand substitution reaction, *Microchem. J.* 88 (2008) 45–51.
- [64] R.G. Pearson, Hard and soft acids and bases, HSAB, part I: Fundamental principles, *J. Chem. Educ.* 45 (1968) 581–586; Hard and soft acids and bases, HSAB, part II: underlying theories, *J. Chem. Educ.* 45 (1968) 643–648.
- [65] G.P. Pandey, A.K. Singh, S. Prasad, L. Deshmukh, A. Asthana, Development of surfactant assisted kinetic method for trace determination of thallium in environmental samples, *Microchem. J.* 118 (2015) 150–157.
- [66] J. Boken, S. Thatai, P. Khurana, S. Prasad, D. Kumar, Highly selective visual monitoring of hazardous fluoride ion in aqueous media using thiobarbituric-capped gold nanoparticles, *Talanta* 132 (2015) 278–284.
- [67] S. Thatai, P. Khurana, S. Prasad, D. Kumar, Plasmonic detection of Cd²⁺ ions using surface-enhanced raman scattering active core-shell nanocomposite, *Talanta* 134 (2015) 568–575.
- [68] R.C. Weast, *CRC Handbook of Chemistry and Physics*, 60th ed. The Chemical Rubber Publishing Company, USA, 1979 D148.
- [69] H. Koszegi-Szalai, T.L. Paal, Equilibrium studies of mercury(II) complexes with penicillamine, *Talanta* 48 (1999) 393–402.
- [70] H. Lineweaver, D. Burk, The determination of enzyme dissociation constants, *J. Am. Chem. Soc.* 56 (1934) 658–666.
- [71] D. Harvey, *Modern Analytical Chemistry*, Mc Graw Hill, Boston, USA, 2000 638.
- [72] Jr.I. Tinoco, K. Sauer, J.C. Wang, *Physical Chemistry, Principles and Applications in Biological Sciences*, Prentice-Hall Inc., New Jersey, USA, 1978 351.
- [73] USP: United States Pharmacopoeia, XXIII Official Monographs, 1995 1163.